Age Related Macular Degeneration Market Research Report 2019: Industry Size, Share, Trends, Growth and Opportunity Assessment, Regional Analysis and Segmentation By Type (Wet AMD & Dry AMD), by Stages (Intermediate AMD, Early AMD, & Late AMD), by Age Group (Above 75, Above 60, & Above 40), by Diagnosis & Treatment, and End-User – Global Forecast Till 2023

The global age-related macular degeneration market was analyzed by Market Research Future (MRFR) and it was projected that a notable CAGR of 8.3% will be attained by the market over the forecast period of 2018 to 2023. The valuation of the age-related macular degeneration market was further stated to surpass its 2017 valuation of 1.37 Billion and reach a projected valuation of USD 2.21 Billion by the end of 2023.

The global age-related macular degeneration market comprises a host of key players. This includes names like Ophthotech Corporation (U.S.), Novartis International AG (Switzerland), Lpath Inc. (U.S.), Neurotech Pharmaceuticals Inc. (U.S.), Gilead Sciences Inc. (U.S.), Bayer AG (Germany), Acucela Inc. (U.S.), Neurotech Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline PLC (U.S.), QLT Inc. (Canada), Allergan PLC (Ireland), Adverum Biotechnologies Inc. (U.S.), Alimera sciences Inc. (U.S.), RXi Pharmaceuticals Inc. (U.S.), Sagent Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Resolvyx Pharmaceuticals Inc. (U.S.), Iconic Therapeutics Inc. (U.S.), StemCell Inc. (Canada), StemCell Inc. (Canada), OHR Pharmaceutical Inc. (U.S.), Pfizer Inc. (U.S.), x Quark (U.S.), Regeneron Pharmaceutical Inc. (U.S.), Alcon Vision Care (U.S.), Bausch + Lomb (U.S.), PanOptica, Inc. (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Opthea Limited (Canada), Sanwa Kagaku Kenkyusho (Japan), and others.

Get a FREE Sample with Complete TOC @ https://www.marketresearchfuture.com/sample_request/5736

Jan 2019, a research team form the University of Liverpool, led by Dr. Louise Porter, published a study report in Clinical Epigenetics, wherein it claimed to have identified new genes that are linked to the development of AMD, one of the biggest cause of blindness.

Market Segmentation

The global Age Related Macular Degeneration Market has been segmented in terms of type, end-user, diagnosis & treatment, age group, route of administration, and stages.

By type, the market segments into dry age-related macular degeneration (Dry AMD) and wet age-related macular degeneration (Wet AMD). The Wet AMD segment holds more than half of the total market share and is projected to garner a CAGR of 7.6% over the forecast period. The fast-paced growth of the segment can be owed to it being a key cause of almost 90% acute blindness and the expanding geriatric population across the globe.

By stages, the market includes late-stage age-related macular degeneration, early-stage age-related macular degeneration, and intermediate age-related macular degeneration. The intermediate age-related macular degeneration segment is reported to be one of the most common forms of AMD across the globe and holds a major portion of the market. The segment is positioned to grow during the forecast period with the fastest CAGR.

By age group, the market comprises above 40 years, above 75 years, and above 60 years. Among these, the above 75 years segment is identified to grow with the fastest CAGR of 7.5% during the forecast period to remain atop of the market standings. The dominance of this age group is due to the common nature of this disease at a later stage of life.

By diagnosis & treatment, the market divides into diagnosis and treatment. The treatment segment accounts for the maximum share of the global AMD market and is expected to grow with the highest CAGR. Various novel treatment methodologies are driving the growth of this segment due to the increasing demand for treating wet AMD.

By route of administration, the market branches down into intravenous route administration and intravitreal route of administration. The intravitreal route of administration segment enjoys a majority of the market share and is slated to grow at an annual pace of 7.7% over the assessment period.

By end-user, the market narrows down into academic research institutes, diagnostic centers, and hospital & clinics. Due to an increasing number of patients looking for treatments of AMD, the hospitals and clinics segment drives a majority of the market share. The segment is primed to grow during the forecast period at an annual rate of 7.6%.

Regional Analysis

The global age-related macular degeneration market is geographically distributed across the following key regions: Asia Pacific, Americas, Europe, and the Rest of the World (RoW). Regionally, the Americas enjoy the highest share in global age-related macular degeneration market. While Asia Pacific is projected to grow at the fastest rate over the forecast period.

Intended Audience

  • Medical Devices Companies
  • Research and Development (R&D) Companies
  • Pharmaceutical Companies
  • Government Research Institutes
  • Academic Institutes and Universities

Get More Information on Age Related Macular Degeneration Market Research Report – Forecast to 2023 @ https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736

List of Tables

Table 1 Age-related Macular Degeneration Industry Synopsis, 2017–2023
Table 2 Age-related Macular Degeneration Market Estimates & Forecast, 2017–2023, (Usd Million)
Table 3 Age-related Macular Degeneration Market, by Region, 2017–2023, (Usd Million)
Table 4 Age-related Macular Degeneration Market, by Type, 2017–2023, (Usd Million)
Table 5 Age-related Macular Degeneration Market, by Drug, 2017–2023, (Usd Million)
Table 6 Age-related Macular Degeneration Market, by Route of Administration, 2017–2023, (Usd Million)
Table 7 Age-related Macular Degeneration Market, by Treatment, 2017–2023, (Usd Million)
Table 8 Age-related Macular Degeneration Market, by End-user, 2017–2023, (Usd Million)
Table 9 North America Age-related Macular Degeneration Market, by Type, 2017–2023, (Usd Million)
Table 10 North America Age-related Macular Degeneration Market, by Drug, 2017–2023, (Usd Million)

Continued……..

List of Figures

Figure 1 Research Process
Figure 2 Segmentation for Age-related Macular Degeneration Market
Figure 3 Segmentation Market Dynamics for Age-related Macular Degeneration Market
Figure 4 Global Age-related Macular Degeneration Market Share, by Type 2016
Figure 5 Global Age-related Macular Degeneration Market Share, by Drug 2016
Figure 6 Global Age-related Macular Degeneration Market Share, by Route of Administration, 2016
Figure 8 Global Age-related Macular Degeneration Market Share, by Treatment, 2016
Figure 9 Global Age-related Macular Degeneration Market Share, by End-user, 2016
Figure 10 Global Age-related Macular Degeneration Market Share, by Region, 2016

Continued……..

Ask for your specific company profile and country level customization on reports.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Edibles.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.





Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *